^
over2years
A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors. (PubMed, Adv Sci (Weinh))
In vivo, WBC100 potently regresses multiple lethal c-Myc overexpressing tumors such as acute myeloid leukemia, pancreatic, and gastric cancers with good tolerability in multiple xenograft mouse models. Identification of the NLS1-Basic-NLS2 region as a druggable pocket for targeting the "undruggable" c-Myc protein and that single-agent WBC100 potently regresses c-Myc overexpressing tumors through selective c-Myc proteolysis opens new perspectives for pharmacologically intervening c-Myc in human cancers.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
MYC overexpression • MYC expression
|
WB100
over2years
Clinical Trial of WB100 on Advanced Solid Tumor (clinicaltrials.gov)
P1, N=60, Recruiting, Zhejiang University | Not yet recruiting --> Recruiting
Enrollment open
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CA 19-9 (Cancer antigen 19-9)
|
MYC overexpression • MYC expression • MYC positive
|
WB100
3years
Clinical Trial of WB100 on Advanced Solid Tumor (clinicaltrials.gov)
P1, N=60, Not yet recruiting, Zhejiang University
Clinical • New P1 trial
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CA 19-9 (Cancer antigen 19-9)
|
MYC overexpression • MYC expression • MYC positive
|
WB100